Incidence of idiopathic cardiomyopathy in patients with type 2 diabetes in Taiwan: age, sex, and urbanization status-stratified analysis

Table 6 Overall relative hazards of idiopathic cardiomyopathy (ICD9 = 425.4; ICD10 = I42.0) in association with anti-diabetic medications use in patients with type 2 diabetes

	Without Cardiomyopathy		With Cardiomyopathy		p value	Total	Adjusted HR^a
	n	%	n	%	p value	Total	Adjusted HR^a
Sulphonylureas
No	109,968	23.26	296	20.56	0.0154	110,264
Yes	362,860	76.74	1144	79.44		364,004	0.98 (0.86–1.13)
Meglitinides
No	363,996	76.98	1077	74.79	0.0486	365,073
Yes	108,832	23.02	363	25.21		109,195	0.85 (0.75–0.95)
Thiazolidinediones
No	316,148	66.86	977	67.85	0.4283	317,125
Yes	156,680	33.14	463	32.15		157,143	0.83 (0.74–0.93)
α-Glucosidase inhibitors
No	314,316	66.48	922	64.03	0.0495	315,238
Yes	158,512	33.52	518	35.97		159,030	0.89 (0.80–1.00)
Metformin
No	85,663	18.12	281	19.51	0.1695	85,944
Yes	387,165	81.88	1159	80.49		388,324	0.80 (0.70–0.92)
Insulin
No	350,379	74.10	824	57.22	< .0001	351,203
Yes	122,449	25.90	616	42.78		123,065	1.59 (1.43–1.78)
Dipeptidyl peptidase 4 inhibitors
No	257,876	54.54	929	64.51	< .0001	258,805
Yes	214,952	45.46	511	35.49		215,463	0.50 (0.45–0.56)
Sodium glucose cotransporter 2 inhibitors
No	461,571	97.62	1438	99.86	< .0001	463,009
Yes	11,257	2.38	2	0.14		11,259	0.06 (0.02–0.24)
Glucagon-like peptide 1 receptor agonists
No	469,889	99.38	1438	99.86	0.0198	471,327
Yes	2939	0.62	2	0.14		2941	0.23 (0.06–0.91)

HR hazard ratio
^aBased on Cox proportional hazard regression with adjustment for age, sex, and urbanization status; status of ischemic heart disease, hypertensive disease, rheumatic heart disease, valvular heart disease, congenital heart disease, acute myocarditis, stroke, obesity, and hyperlipidemia; and antihypertensive medications use

ISSN: 1475-2840